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Summary
Background: We performed a case—control study to assess the relationship between vascular
endothelial growth factor (VEGF) and its soluble receptors (sVEGFR-1 and 2) in adult patients with
dengue fever (DF) and dengue hemorrhagic fever (DHF).
Methods: We recruited 60 adult patients (34 DF and 26 DHF) with serologically-confirmed dengue
infections, 10 patients with non-hemorrhagic infections, and 31 community-based healthy
volunteers. The levels of VEGF, sVEGFR-1, and sVEGFR-2 were measured and the differences
in these markers were compared using one-way analysis of variance (ANOVA), which was adjusted
for multiple comparisons.
Results: We observed lower VEGF levels in DF and DHF compared to study controls ( p < 0.01).
sVEGFR-1 was higher in DHF than DF, whilst sVEGFR-2 was lower in DF and DHF compared to study
controls (all p < 0.01). In DHF, lower VEGF levels were observed in older patients. The use of a
single marker, sVEGFR-1 >350 pg/ml, was predictive of DHF.
Conclusion: The changes in VEGF and its soluble receptors highlight the importance of vascular
permeability cytokines in the pathogenesis of DHF.
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Dengue is an emerging infectious disease globally.1,2 An
estimated 2.5 billion people living in populous tropical and
subtropical countries such as South and Southeast Asia are at
risk of contracting dengue,1 which can range from mildPublished by Elsevier Ltd. All rights reserved.
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and dengue hemorrhagic fever (DHF)) infections. Increased
plasma leakage, a hallmark of DHF, manifests clinically as
pleural effusion, ascites, and circulatory shock.1,2 In DF,
plasma leakage is transient and generally lasts for less than
48 hours, followed by rapid and complete recovery.1,2 In DSS,
the longer duration and greater extent of plasma leakage is
associated with increased mortality, ranging from 1% to 5% in
those with circulatory shock.2 Certain population subgroups,
such as the elderly and those with secondary dengue infec-
tion, are more susceptible to an increase in plasma leakage.2
Plasma leakage in DHF is unique, as it occurs with a relative
lack of tissue inflammation3 compared to other viral hemor-
rhagic fevers, e.g. hantavirus pulmonary syndrome and
hemorrhagic fever with renal syndrome, where tissue inflam-
mation is prominent.4
Vascular endothelial growth factor (VEGF), a potent per-
meability-enhancing cytokine, is thought to play a pivotal role
in mediating plasma leakage in DHF.5—8 Tseng et al. observed
elevated circulating VEGF levels in adult DHF patients who
were admitted during the early phases of dengue infection,
compared to patients with DF and study controls.5 In children,
Srikiatkhachorn et al. observed a rise in circulating VEGF in
DHF in the early febrile and defervescent stages of dengue
infection, but not during the later convalescent stage.7 A
subsequent study, however, had contradictory findings. Sathu-
pan et al. did not observe any increase in the concentration of
circulating VEGF during the early febrile and toxic stages in
DHF, but found instead lower VEGF concentrations in patients
with more severe dengue infection.6 Several reasons may
explain these differences, such as poor study design, small
sample size, and the lack of a standardized collection meth-
odology and storage of blood samples used for the measure-
mentofVEGF.Weperformedacase—control study toassess the
relationship between VEGF and its soluble receptors in adult
patients with DF and DHF. We also sought to determine if VEGF
and its soluble receptors could identify patients at risk of
developing DHF.
Methods
Cases
Cases (N = 60) were patients with dengue infection, aged 21
years andabove,whohad received clinical careat theNational
University Hospital, Singapore, from October to December
2005. They were assessed within 24 hours of hospitalization
using a standardized questionnaire.9 Demographic (age, gen-
der and ethnicity) and clinical characteristics (history of
hypertension, diabetes mellitus, ischemic heart disease and
dyslipidemia) were obtained from these patients. Twenty
milliliters of blood were drawn using the Vacutainer (Becton
Dickinson, UK) system within 24 hours of hospitalization, col-
lected in plain glass tubes and allowed to coagulate for 60 min
prior to spinningdownand freezing at80 8C,pendinganalysis
for VEGF and its soluble receptors.
The cases were classified as DF and DHF based on the
recommendations of the World Health Organization.2 DHF
was considered in patients who demonstrated plasma leakage
(hypoproteinemia and pleural effusion on chest radiographs),
thrombocytopenia (platelet count<100  109/l), and hemor-
rhagic tendencies.2 Hemorrhagic tendencies included apositive tourniquet test, skin bleeding (petechiae, ecchymo-
sis, or purpura), mucosal bleeding (epistaxis, gum bleeding,
or other sites), hematemesis, or melena.2 We included those
who manifested a four-fold rise in IgG antibodies against
dengue, measured in acute and convalescent sera using a
double sandwich capture ELISA as previously described.10
Patients with no serological confirmation of dengue virus
infection were excluded. Dengue virus RNA was amplified
by reverse transcriptase nested PCR using the method of
Lanciotti et al.11
Controls
Patients with non-hemorrhagic infections admitted to our
hospital and community-based healthy volunteers were
recruited as study controls. Demographic (age, gender and
ethnicity), clinical characteristics (history of diabetes,
hypertension, dyslipidemia and smoking), and blood samples
were obtained from these participants using standardized
methods. Written informed consent was obtained from all
study participants. The study was approved by our hospital’s
domain specific institutional review board and conformed to
the tenets of the Declaration of Helsinki.
Measurement of VEGF and its soluble receptors
(sVEGFR-1 and 2)
Serum samples were analyzed for free circulating VEGF using
a commercially available sandwich ELISA (Endogen, Pierce
Biotechnology, Inc., IL, USA), whilst sVEGFR-1 and sVEGFR-2
were analyzed using assays from R&D Systems (Quantikine
human sVEGF R1 and 2). These assays have been used in many
previous studies and have a low inter- and intra-assay error
range (intra-assay error 6.7—4.5 percentage coefficient of
variation (%CV), inter-assay error 8.8—6.2 %CV). To measure
VEGF, the microplate was coated with anti-human VEGF165
antibody that captured VEGF to the plate. After non-bound
proteins were removed, a biotinylated detecting antibody
was added, which bound to a second site on the VEGF. Excess
detecting antibody was removed and streptavidin—horserad-
ish peroxidase was added, reacting with tetramethylbenzi-
dine (TMB) to produce a colorimetric signal.
To measure sVEGFR-1 and sVEGFR-2, standards and sam-
ples were pipetted into wells that were precoated with a
monoclonal antibody specific for VEGFR-1/2. After washing
away any unbound substances, a substrate solution was
added to the wells and color developed in proportion to
the amount of bound VEGFR-1/2. The color development
was then stopped and the colorimetric signal measured. All
analyses and calibrations were carried out in duplicate and
the optical densities were determined at 450 and 550 nm.
The concentration of VEGF in the tested samples was esti-
mated from the standard curve, which was determined by
serially diluted standards. Concentrations were reported in
pg/ml.
Sample size calculation
Using data from a pilot study, we anticipated that cases with
dengue infection would have VEGF concentrations >200 pg/
ml lower than study controls. The mean VEGF for the study
controls was estimated at 300 pg/ml (range 100—10 000 pg/
e250 R.C.S. Seet et al.ml) in our population. Using a conservative standard devia-
tion of 250 (approximately a quarter of the range), we
calculated that 26 subjects in each group would have a power
of 80% with a two-sided 5% statistical significance.
Statistical analysis
All statistical analyses were conducted using SPSS software
(version 15.0; SPSS Inc., Chicago, IL, USA) and statistical
significance was set at p < 0.05. The differences in VEGF,
sVEGFR-1, and sVEGFR-2 amongst subjects with DF, DHF, and
study controls were assessed using one-way analysis of var-
iance (ANOVA) with Bonferroni adjustments for multiple
comparisons. Multivariate analyses using the general linear
model were performed. Pearson correlation analysis was
used to assess the relationship between these permeability
markers with age. We developed prediction models to differ-
entiate DHF from DF using regression analyses.
To identify the optimum cutoff value, we used the Youden
index (sensitivity + specificity  1) as ameasure of accuracy.12
Results
Clinical characteristics
One hundred and one volunteers participated in this study: 34
had DF, 26 had DHF, 10 had non-hemorrhagic infections, and
31were study controls (Table 1). Themean age, male/female
gender ratios, and the proportion of those with medical co-
morbidities such as hypertension, diabetesmellitus, ischemic
heart disease, and dyslipidemia were not different between
these groups ( p-values 0.30—0.80; Table 1). Dengue virus
serotype DEN-2 was isolated in 10 (17%) patients, DEN-1 in
four (7%), and DEN-4 in one (2%).
VEGF and its soluble receptors (sVEGFR-1 and
sVEGFR-2)
The mean VEGF levels were 158 (standard deviation (SD) 91)
pg/ml in DF, 115 (SD 86) pg/ml in DHF, 360 (SD 82) pg/ml in
non-hemorrhagic infection controls, and 365 (SD 190) pg/mlTable 1 Clinical characteristics of patients with dengue fever a
Variables Dengue fever
(n = 34)
Dengue hemorrha
fever (n = 26)
Age, mean (SD)a 37 (12.0) 38 (13.7)
Gender (%)b
Male 21 (62) 16 (62)
Female 13 (38) 10 (38)
Medical history (%)b
Hypertension 3 (9) 0
Diabetes 0 1 (4)
Ischemic heart disease 0 1 (4)
Dyslipidemia 1 (3) 2 (8)
Onset of symptoms
(days), mean (SD)
4.76 (1.6) 4.36 (1.2)
a ANOVA analysis.
b Chi-square test.in healthy controls (Figure 1). Although there was no differ-
ence in the VEGF concentration between the DF and DHF
groups ( p = 0.41), their mean concentrations were signifi-
cantly lower compared to the study controls (non-hemor-
rhagic infectious diseases and healthy volunteers) ( p < 0.01;
Figure 1A). The mean sVEGFR-1 concentration was 278 (SD
126) pg/ml in DF, 427 (SD 136) pg/ml in DHF, 247 (SD 88) pg/ml
in non-hemorrhagic infection controls, and 219 (SD 208) pg/
ml in healthy controls. The increased levels of sVEGFR-1 were
significantly higher amongst those with DHF compared to
those with DF and study controls (non-hemorrhagic infection
and healthy volunteers) ( p < 0.01; Figure 1B). The mean
sVEGFR-2 was 6559 (SD 1569) pg/ml in DF, 5749 (SD 1562)
pg/ml in DHF, 7589 (SD 579) pg/ml in non-hemorrhagic
infection controls, and 8518 (SD 1471) pg/ml in healthy
controls (Figure 1C). The mean difference in sVEGFR-2
between DF and DHF was not statistically significant
( p = 0.76), but both values were significantly lower than
those of the study controls ( p < 0.01). No differences were
found between these markers and gender.
In DHF, VEGF levels were lower in older patients (VEGF vs.
age, r = 0.55, p = 0.04; Figure 2A). VEGF was negatively
correlated with sVEGFR-1 (r = 0.67, p = 0.02) (Figure 2B),
but not with sVEGFR-2 (r = 0.23, p = 0.82). No significant
relationship was observed between VEGF/sVEGFR-2 and age
in DF and in study controls. As sVEGFR-1 was significantly
higher in DHF patients, we developed a prediction model to
assess the use of sVEGFR-1 to identify DHF. At an optimal
sVEGFR-1 cut-off of >350 pg/ml, the positive and negative
predictive values of identifying DHF were 76% and 81%
respectively, with a sensitivity of 79% and specificity of
78% (area under the receiver operating characteristics curve
0.79, 95% confidence interval 0.65—0.92).
Discussion
VEGF is present in a soluble and bound form, and interacts
with two tyrosine kinase receptors,13,14 VEGFR-1 and VEGFR-
2, to promote angiogenesis and vascular integrity.13 VEGF
binds to VEGFR-2 to induce the phosphorylation and activa-
tion of endothelial VEGFR-2.13 Although the downstream cellnd dengue hemorrhagic fever, and study controls
gic Non-hemorrhagic
infection (n = 10)
Healthy controls
(n = 31)
p-Values
36 (5.) 40 (13.1) 0.76
0.60
5 (50) 16 (52)
5 (50) 15 (48)
1 (10) 1 (3) 0.80
0 1 (3) 0.50
0 0 0.30
1 (10) 2 (6) 0.71
3.9 (0.5) — 0.59
Figure 1 Comparison of soluble (A) vascular endothelial growth factor (VEGF), (B) soluble vascular endothelial growth factor
receptor 1 (sVEGFR-1), and (C) soluble vascular endothelial growth factor receptor 2 (sVEGFR-2) concentrations during dengue fever,
dengue hemorrhagic fever, and in control groups (control 1 = non-hemorrhagic infection, control 2 = healthy volunteers).
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ventional studies in animals15 and humans14 suggest that
VEGFR-1 may protect against circulatory shock (Figure 3).
In this study, we observed lower concentrations of circulating
VEGF and soluble VEGFR-2 in patients with DF and DHF. By
clustering the patients into different age groups, we found
the extent of fall in VEGF levels to be greater in older
patients above the age of 45 years. We also propose the
potential clinical use of vascular permeability factors (suchFigure 2 Relationship between age quartiles and (A) vascular endo
growth factor receptor 1 (sVEGFR-1) (Q1 = <28 years, Q2 = 28—35 yas sVEGFR-1) to help clinicians identify patients who are at a
higher risk of developing DHF.
Previous in vitro studies have shown that exposure of
endothelia to live dengue virus results in decreased produc-
tion of the sVEGFR-2 and enhanced surface VEGFR-2 expres-
sion.7 In vivo studies have similarly shown that plasma viral
load correlates with a decline in sVEGFR-2.7 The synchronous
lowering of circulating VEGF and sVEGFR-2 levels may be
explained by a higher binding of the VEGF to its R2 receptorsthelial growth factor (VEGF) and (B) soluble vascular endothelial
ears, Q3 = 35—45 years, Q4 = >45 years; p < 0.01, ANOVA).
Figure 3 Circulating vascular endothelial growth factor
(VEGF) binds to VEGF receptors (VEGFR-1 and VEGFR-2) to form
VEGF—receptor complex, which becomes internalized by the cell
in endosomes. In excess, loss of intercellular barrier occurs,
resulting in an increase in vascular permeability and extravasa-
tion of red cells into the surrounding tissues.
e252 R.C.S. Seet et al.to form VEGF—receptor complexes (Figure 3). We observed a
significant rise in the concentration of sVEGFR-1 in DHF
compared to DF and study controls, a finding similar to that
of previous studies in dengue,7 and in other diseases such as
preeclampsia16 and severe sepsis.14 It is not known whether
sVEGFR-1 acts to aggravate or ameliorate vascular perme-
ability in DHF, although current evidence suggests that
sVEGFR-1 may have a protective effect in sepsis by inhibiting
binding of VEGF to its R2 receptors.14,15,17 In experimental
animal models of endotoxemia and sepsis, treatment with
sVEGFR-1 attenuated inflammatory responses, inhibited
recruitment of inflammatory cells into the peritoneal cavity,
and improved survival, even when administered as late as
24 hours after the onset of sepsis.15,17 We also highlight the
potential use of a single marker (sVEGFR-1) as a new marker
to identify patients at risk of early DHF.
The changes in VEGF and its receptors with age are
intriguing. In ophthalmic diseases, VEGF has been shown to
play a pivotal role in the mechanism of age-related macular
degeneration by modulating the expression of inflammation
and oxidative stress in the eyes.18 In DHF, we provide further
evidence that changes in the circulating levels of VEGF are
altered according to age. The levels of sVEGFR-1 were
increased with age, but no relationship was observed
between sVEGFR-2 and age. We postulate that the lower
levels of circulating VEGF are a result of an increased binding
of VEGF to its receptor and the rise in sVEGFR-1, a response to
the bound form of VEGF. An increase in the age-related
structural change coupled with lower regenerative capacity
in the senescent endothelium, may possibly reduce the
ability of the endothelial cell to limit the extent of the
vascular permeability in DHF.
Our study has several limitations. First, we managed to
identify the dengue serotype in only 15 (25%) patients and
were not able to analyze the concentration of VEGF and its
soluble receptors according to dengue serotype. This may be
important, as a recent study has suggested that the dengue
serotype may influence the expression of angiogenic-specificcytokine following exposure to the dengue virus.8 Second, it
is unclear if circulating VEGF is more accurately measured
using serum or plasma samples. Although we followed a
standardized protocol to collect serum samples, which were
allowed to clot for 60 min to ensure thorough platelet acti-
vation before centrifugation and freezing, the possibility of
the physiological release of VEGF from platelet activation
cannot be discounted. Previous studies whichmeasured VEGF
in both serum and plasma samples, however, did not observe
differences in their conclusions when investigating patients
with acute dengue infection6 and in healthy females during
their menstrual cycle.19 Third, we did not include children in
our study, which would have been useful to evaluate the
influence of age on the vascular permeability in patients with
DF and DHF. These limitations, however, should be set against
the prospective case—control study design.
Further studies are needed to determine the influence of
the dengue serotypes on changes in VEGF in DF and DHF at
different time-points of infection, the potential protective
effects of the sVEGFR-1 to reduce the extent of vascular
permeability in DHF, and the validation of the use of vascular
permeability factors in triage patients at higher risk of
developing DHF for closer clinical care. Measurements of
markers that reflect endothelial function, inflammation,
and oxidative stress damage in future studies would enable
us to understand the biological significance of these findings.
Acknowledgement
Financial support was given by the National Medical Research
Council, Singapore (grant number R-172-000-154-214).
Conflict of interest: No conflict of interest to declare.
References
1. Halstead SB. Dengue. Lancet 2007;370:1644—52.
2. World Health Organization. Dengue hemorrhagic fever: diagno-
sis, treatment, prevention and control. 2nd ed. Geneva: World
Health Organization; 1997.
3. Bhamarapravati N, Tuchinda P, Boonyapaknavik V. Pathology of
Thailand haemorrhagic fever: a study of 100 autopsy cases. Ann
Trop Med Parasitol 1967;61:500—10.
4. Peters CJ, Zaki SR. Role of the endothelium in viral hemorrhagic
fevers. Crit Care Med 2002;30(5 Suppl):S268—73.
5. Tseng CS, Lo HW, Teng HC, Lo WC, Ker CG. Elevated levels of
plasma VEGF in patients with dengue hemorrhagic fever. FEMS
Immunol Med Microbiol 2005;43:99—102.
6. Sathupan P, Khongphattanayothin A, Srisai J, Srikaew K, Poovor-
awan Y. The role of vascular endothelial growth factor leading to
vascular leakage in children with dengue virus infection. Ann
Trop Paediatr 2007;27:179—84.
7. Srikiatkhachorn A, Ajariyakhajorn C, Endy TP, Kalayanarooj S,
Libraty DH, Green S, et al. Virus-induced decline in soluble
vascular endothelial growth receptor 2 is associated with plasma
leakage in dengue hemorrhagic fever. J Virol 2007;81:1592—600.
8. Azizan A, Sweat J, Espino C, Gemmer J, Stark L, Kazanis D.
Differential proinflammatory and angiogenesis-specific cytokine
production in human pulmonary endothelial cells. HPMEC-ST1.
6R infected with dengue-2 and dengue-3 virus. J Virol Methods
2006;138:211—7.
9. SeetRC,Ooi EE,WongHB,PatonNI.Anoutbreakofprimarydengue
infection among migrant Chinese workers in Singapore character-
ized by prominent gastrointestinal symptoms and a high propor-
tion of symptomatic cases. J Clin Virol 2005;33:336—40.
VEGF and sVEGFR-1/2 in dengue virus infection e25310. Innis BL, Nisalak A, Nimmannitya S, Kusalerdchariya S, Chongs-
wasdi V, Suntayakorn S, et al. An enzyme-linked immunosorbent
assay to characterize dengue infections where dengue and
Japanese encephalitis co-circulate. Am J Trop Med Hyg 1989;
40:418—27.
11. Lanciotti RS, Calisher CH, Gubler DJ, Chang GJ, Vorndam AV.
Rapid detection and typing of dengue viruses from clinical
samples by using reverse transcriptase-polymerase chain reac-
tion. J Clin Microbiol 1992;30:545—51.
12. Youden WJ. Index for rating diagnostic tests. Cancer 1950;3:
32—5.
13. Nachman RL, Rafii S. Platelets, petechiae, and preservation of
the vascular wall. N Engl J Med 2008;359:1261—70.
14. ShapiroNI, Yano K,Okada H, Fischer C, Howell M, Spokes KC, et al.
A prospective, observational study of soluble FLT-1 and vascular
endothelial growth factor in sepsis. Shock 2008;29:452—7.15. Tsao PN, Chan FT, Wei SC, Hsieh WS, Chou HC, Su YN, et al.
Soluble vascular endothelial growth factor receptor-1 protects
mice in sepsis. Crit Care Med 2007;35:1955—60.
16. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al.
Circulating angiogenic factors and the risk of preeclampsia. N
Engl J Med 2004;350:672—83.
17. Yano K, Liaw PC, Mullington JM, Shih SC, Okada H, Bodyak N, et al.
Vascular endothelial growth factor is an important determinant of
sepsis morbidity and mortality. J Exp Med 2006;203:1447—58.
18. Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett
ME. Vascular endothelial growth factor in eye disease. Prog Retin
Eye Res 2008;27:331—71.
19. McIlhenny C, GeorgeWD, Doughty JC. A comparison of serum and
plasma levels of vascular endothelial growth factor during the
menstrual cycle in healthy female volunteers. Br J Cancer 2002;
86:1786—9.
